HER2阳性乳腺癌的靶向治疗
Targeted therapy in HER2-positive breast cancer.
作者信息
Li Shu Guang, Li Li
机构信息
Department of Chemotherapy, Cancer Center, Qilu Hospital of Shandong University, Jinan, Shandong 250012, P.R. China.
出版信息
Biomed Rep. 2013 Jul;1(4):499-505. doi: 10.3892/br.2013.95. Epub 2013 Apr 18.
Abstract
Treatment options for breast cancer vary based on tumor surface markers and clinical factors, including cytotoxic chemotherapy, hormonal therapy, biological therapy or a combination thereof. An important molecular determinant of therapy is the human epidermal growth factor receptor 2 (HER2) positivity of the tumor, which has been identified in 20-25% of breast cancers and is a prognostic marker of poor outcome. The advent of HER2-targeted therapies has significantly improved the survival of patients with HER2-positive breast cancer. This review focuses on current HER2-targeted therapeutic options for patients with HER2-positive breast cancer, including monoclonal antibodies and tyrosine kinase inhibitors (TKIs).
摘要
乳腺癌的治疗方案因肿瘤表面标志物和临床因素而异，包括细胞毒性化疗、激素治疗、生物治疗或它们的组合。治疗的一个重要分子决定因素是肿瘤的人表皮生长因子受体2（HER2）阳性，在20%-25%的乳腺癌中已被确定，并且是预后不良的一个标志物。HER2靶向治疗的出现显著提高了HER2阳性乳腺癌患者的生存率。本综述重点关注HER2阳性乳腺癌患者当前的HER2靶向治疗选择，包括单克隆抗体和酪氨酸激酶抑制剂（TKIs）。
相似文献
1
Targeted therapy in HER2-positive breast cancer.HER2阳性乳腺癌的靶向治疗
Biomed Rep. 2013 Jul;1(4):499-505. doi: 10.3892/br.2013.95. Epub 2013 Apr 18.
2
Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.阻断 HER 家族受体在治疗 HER2 阳性转移性乳腺癌中的作用。
Clin Breast Cancer. 2012 Feb;12(1):19-29. doi: 10.1016/j.clbc.2011.07.001. Epub 2011 Sep 8.
3
Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.接受靶向治疗的乳腺癌脑转移分子亚型的总生存期及放疗反应
Cancer. 2017 Jun 15;123(12):2283-2293. doi: 10.1002/cncr.30616. Epub 2017 Feb 13.
4
Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.HER2阳性乳腺癌中酪氨酸激酶抑制剂的临床进展
Front Pharmacol. 2022 Dec 12;13:1089066. doi: 10.3389/fphar.2022.1089066. eCollection 2022.
5
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now.人表皮生长因子受体2阳性乳腺癌与酪氨酸激酶抑制剂：时机已至。
NPJ Breast Cancer. 2021 May 20;7(1):56. doi: 10.1038/s41523-021-00265-1.
6
Lapatinib.拉帕替尼
Recent Results Cancer Res. 2018;211:19-44. doi: 10.1007/978-3-319-91442-8_2.
7
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.描绘HER2抑制剂耐药的生物标志物：对HER2阳性乳腺癌治疗的启示
Cancers (Basel). 2024 Jul 24;16(15):2635. doi: 10.3390/cancers16152635.
8
New protein kinase inhibitors in breast cancer: afatinib and neratinib.乳腺癌中的新型蛋白激酶抑制剂：阿法替尼和来那替尼。
Expert Opin Pharmacother. 2014 Jun;15(9):1277-88. doi: 10.1517/14656566.2014.913570. Epub 2014 Apr 30.
9
HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future.HER2阳性早期乳腺癌的HER2靶向治疗：现状与未来。
Front Pharmacol. 2024 Sep 16;15:1446414. doi: 10.3389/fphar.2024.1446414. eCollection 2024.
10
A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers.HER2阳性恶性肺癌治疗进展与生存预后的叙述性综述
J Thorac Dis. 2021 Jun;13(6):3708-3720. doi: 10.21037/jtd-20-3265.
引用本文的文献
1
Comparative survival analysis of HER2-positive Pregnancy-Associated Breast Cancer (PABC) and non-Pregnancy-Associated breast Cancer (non-PABC) cohorts: a matched control study.人表皮生长因子受体2（HER2）阳性妊娠相关乳腺癌（PABC）与非妊娠相关乳腺癌（non-PABC）队列的生存比较分析：一项匹配对照研究。
BMC Cancer. 2025 Aug 1;25(1):1252. doi: 10.1186/s12885-025-14602-1.
2
Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer.白藜芦醇作为癌症化学增敏剂和放射增敏剂的分子机制
Front Pharmacol. 2023 Nov 10;14:1287505. doi: 10.3389/fphar.2023.1287505. eCollection 2023.
3
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer.不可逆的 HER2 抑制剂克服了非 HER2 扩增腔乳腺癌对 RSL3 铁死亡诱导剂的耐药性。
Cell Death Dis. 2023 Aug 18;14(8):532. doi: 10.1038/s41419-023-06042-1.
4
A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer.基于玛格妥昔单抗治疗HER2阳性转移性乳腺癌患者的综述
Cancers (Basel). 2022 Dec 21;15(1):38. doi: 10.3390/cancers15010038.
5
Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review.曲妥珠单抗治疗相关 HER2 阳性乳腺癌心脏毒性的遗传和 RNA 相关分子标志物：系统评价。
BMC Cancer. 2022 Apr 12;22(1):396. doi: 10.1186/s12885-022-09437-z.
6
Predicting cancer outcomes with radiomics and artificial intelligence in radiology.利用放射组学和人工智能技术预测癌症预后。
Nat Rev Clin Oncol. 2022 Feb;19(2):132-146. doi: 10.1038/s41571-021-00560-7. Epub 2021 Oct 18.
7
Is Curcumin the Answer to Future Chemotherapy Cocktail?姜黄素会成为未来化疗鸡尾酒的答案吗？
Molecules. 2021 Jul 17;26(14):4329. doi: 10.3390/molecules26144329.
8
Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.可溶性细胞质表达和纯化免疫毒素 HER2(scFv)-PE24B 作为麦芽糖结合蛋白融合体。
Int J Mol Sci. 2021 Jun 17;22(12):6483. doi: 10.3390/ijms22126483.
9
The many facets of Notch signaling in breast cancer: toward overcoming therapeutic resistance.Notch 信号在乳腺癌中的多方面作用：克服治疗抵抗。
Genes Dev. 2020 Nov 1;34(21-22):1422-1438. doi: 10.1101/gad.342287.120.
10
Somatic Mutations in and Implications for Current Treatment Paradigms in -Positive Breast Cancer.三阴乳腺癌中的体细胞突变及其对当前治疗模式的影响
J Oncol. 2020 Mar 7;2020:6375956. doi: 10.1155/2020/6375956. eCollection 2020.
本文引用的文献
1
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.一项评估拉帕替尼联合白蛋白紫杉醇用于 HER2 过表达转移性乳腺癌患者的 II 期研究，这些患者既往接受的化疗方案不超过一种。
Breast Cancer Res Treat. 2013 Jan;137(2):457-64. doi: 10.1007/s10549-012-2341-9. Epub 2012 Dec 8.
2
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.曲妥珠单抗治疗后 ErbB2 阳性转移性乳腺癌患者使用奈拉替尼（HKI-272）联合长春瑞滨治疗的安全性和有效性。
Ann Oncol. 2013 Jan;24(1):109-16. doi: 10.1093/annonc/mds284. Epub 2012 Sep 11.
3
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival.亚洲人 HER2 阳性乳腺癌患者的脑转移：抗 HER2 治疗及其对生存的影响。
Br J Cancer. 2012 Sep 25;107(7):1075-82. doi: 10.1038/bjc.2012.346. Epub 2012 Aug 23.
4
Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence.拉帕替尼、曲妥珠单抗或联合用于乳腺癌术前化疗：随机证据的荟萃分析。
Breast Cancer Res Treat. 2012 Oct;135(3):655-62. doi: 10.1007/s10549-012-2189-z. Epub 2012 Aug 9.
5
Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.在韩国开展的一项开放性扩展准入研究：曲妥珠单抗联合卡培他滨治疗 HER2 阳性转移性乳腺癌伴脑转移患者的临床结局。
BMC Cancer. 2012 Jul 28;12:322. doi: 10.1186/1471-2407-12-322.
6
FDA approves pertuzumab for breast cancer.美国食品药品监督管理局批准帕妥珠单抗用于治疗乳腺癌。
Am J Health Syst Pharm. 2012 Jul 15;69(14):1178. doi: 10.2146/news120049.
7
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.曲妥珠单抗联合拉帕替尼治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者的总生存获益：EGF104900 研究的最终结果。
J Clin Oncol. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725. Epub 2012 Jun 11.
8
A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.曲妥珠单抗-美坦新偶联物治疗既往接受曲妥珠单抗、拉帕替尼、蒽环类药物、紫杉烷和卡培他滨治疗的人表皮生长因子受体 2 阳性转移性乳腺癌患者的 II 期研究。
J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29.
9
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.一项关于阿法替尼（BIBW 2992）的 II 期研究，阿法替尼是一种不可逆的 ErbB 家族阻滞剂，用于曲妥珠单抗治疗后进展的 HER2 阳性转移性乳腺癌患者。
Breast Cancer Res Treat. 2012 Jun;133(3):1057-65. doi: 10.1007/s10549-012-2003-y. Epub 2012 Mar 15.
10
What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?目前乳腺癌抗 HER2 新辅助治疗的标准护理方法是什么？
Oncology (Williston Park). 2012 Jan;26(1):20-6.
Zotero 插件